FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3086743547> ?p ?o ?g. }

• W3086743547 endingPage "2364" @default.
• W3086743547 startingPage "2362" @default.
• W3086743547 abstract "Portal hypertension (PHT) is the trigger of the severe complications of cirrhosis, including esophagogastric variceal bleeding (EVB), ascites, hepatic encephalopathy, cirrhotic cardiomyopathy, acute kidney injury and hepatorenal syndrome (AKI-HRS), which may cause death or increase the need for liver transplantation.[1,2] Of these, EVB remains one of the deadliest complications of PHT. As of now, the most widely accepted measure to assess portal pressure (PP) and PHT is the hepatic venous pressure gradient (HVPG) via transjugular-hepatic vein balloon catheterization.[3] The pharmacological management of PHT aims to reduce PP and prevent PHT-related complications.[4,5] Given that PP is determined by portal blood flow and hepatic vascular resistance,[4] currently used drugs are mainly targeted to modulate the increased liver blood flow, such as reducing hyperdynamic circulation, renin-angiotensin-aldosterone system activation, vascular hyperplasia, and collateral circulation formation, or decrease intravascular resistance, such as inhibiting liver fibrosis, regenerative nodules, and angiogenesis.[6] In the setting of PHT, arterial vasodilation occurs both in the splanchnic and systemic circulation, therefore, activates the neurohumoral and vasoconstrictive systems, which leads to sodium and water retention, increased blood volume, and increased cardiac output.[7] Terlipressin, somatostatin (SMT) or octreotide, and non-selective β-blockers (NSBBs) decrease the portal venous inflow through splanchnic vasoconstriction. However, the cross-talk between vasoactive substances and contractile cells often leads to abnormal liver microcirculation and PHT development.[6] Those may be new targets for the pharmacological management of PHT in the future. In clinical practice, SMT and octreotide are usually used to treat PHT-induced acute variceal bleeding (AVB) independently or combined with urgent endoscopic therapy [Table 1].[8–10] A meta-analysis of 30 randomized controlled trials comprising in total of 3344 patients indicated that terlipressin combined with endoscopic variceal ligation had a lower 5-day treatment failure rate and transfusion requirement than terlipressin alone.[11] Furthermore, the combination of SMT/octreotide and endoscopic therapy is effective in controlling AVB.[12] The efficacy of these drugs combined with α-adrenergic receptors activators, such as noradrenaline and midodrine, have also been evaluated in the treatment of AKI-HRS.[3,9] Recent evidence suggests that the efficacy of terlipressin with albumin is superior to midodrine combined with octreotide. The use of terlipressin and albumin in a timely fashion significantly improves AKI-HRS in cirrhotic patients with ascites.[13,14] This approach is also as effective as noradrenaline to reverse AKI-HRS in cirrhotic patients with PHT. [12,14]Table 1: Clinical practice guidelines for the management of esophagogastric variceal bleeding in cirrhotic patients with portal hypertension.As the mainstream drugs for long-term treatment in cirrhotic patients with PHT, NSBBs are used to prevent the primary and secondary EVB and reduce the risk of hepatic decompensation.[15] However, only 30% to 40% of patients treated with long-term NSBBs achieve a response to reduce HVPG. Also, NSBBs may lead to undesirable outcomes, for example, portal vein thrombosis (PVT), AKI, in a portion of cirrhotic patients (odds ratio 4.62, 95% confidence interval 2.50–8.53; P < 0.001) due to remarkably decreased portal vein velocity.[15] Although carvedilol treatment achieves a good hemodynamic response in propranolol non-responders, it may break the delicate hemodynamic balance in cirrhotic patients and increase mortality.[16] To date, multiple new drugs, including statins, anticoagulants, pioglitazone, sorafenib, PX20606, tetrahydrobiopterin, antioxidants, or supplementary treatment such as caffeine and green tea polyphenol, have been reported to benefit PHT patients or animal models. Among them, statins are promising in dealing with PHT in the setting of non-alcoholic steatohepatitis related cirrhosis, by improving liver sinusoidal endothelial cells function and reducing intrahepatic resistance through inhibition of Rho-associated kinase signaling and activation of endothelial nitric oxide synthase.[17] Besides statins, low-molecular-weight heparin or direct-acting anticoagulants (DOACs) are capable of increasing PVT recanalization without extra bleeding and decreasing the incidence of EVB in cirrhotic patients with PVT.[18] Moreover, an observational study shows that DOACs are safe and effective in preventing PVT, delaying hepatic decompensation, and improving prognosis in patients with cirrhosis.[12] It is suggested that DOACs may be safe and effective in patients with compensated cirrhosis. However, further studies are needed to determine the optimal type of anticoagulant and dose in patients with compensated and decompensated cirrhosis. Non-cirrhotic portal hypertension (NCPH) is a disease entity due to rare hepatic sinus-portal vascular diseases or systemic diseases. NCPH is characterized by normal liver function, normal or low HVPG, ascites, splenomegaly, and easily occurrence of EVB. It is noteworthy that NCPH can be easily misdiagnosed as cirrhotic portal hypertension. For NCPH-induced EVB, endoscopic and drug therapies are safe and effective in current clinical practice.[19,20] In summary, pharmacological management is the mainstay of PHT in cirrhotic or NCPH patients. Terlipressin, SMT, and octreotide are the first-line drugs for treating AVB in patients with PHT. Propranolol and carvedilol are recommended for the long-term treatment of cirrhotic PHT. Whether these drugs, especially NSBBs, are also safe and efficient in NCPH patients requires further investigation. Novel therapeutic drugs, which could effectively reduce PP, are needed in clinical practice. Funding This work was supported by grants from the State Key Projects Specialized on Infectious Diseases (No. 2017ZX10203202-004), the National Natural Science Foundation (No. 81970525), the Beijing Natural Science Foundation Program and Scientific Research Key Program of Beijing Municipal Commission of Education (No. KZ201810025037), and the Beijing Municipal Administration of Hospitals’ Ascent Plan (No. DFL20151602). Conflicts of interest None." @default.
• W3086743547 created "2020-09-21" @default.
• W3086743547 creator A5029367861 @default.
• W3086743547 creator A5044741816 @default.
• W3086743547 creator A5079347787 @default.
• W3086743547 creator A5086812005 @default.
• W3086743547 date "2020-09-11" @default.
• W3086743547 modified "2023-09-26" @default.
• W3086743547 title "Pharmacological management of portal hypertension: current status and future" @default.
• W3086743547 cites W2408502477 @default.
• W3086743547 cites W2469879153 @default.
• W3086743547 cites W2546046192 @default.
• W3086743547 cites W2610258648 @default.
• W3086743547 cites W2772840858 @default.
• W3086743547 cites W2802906787 @default.
• W3086743547 cites W2902386013 @default.
• W3086743547 cites W2910000782 @default.
• W3086743547 cites W2913842218 @default.
• W3086743547 cites W2917487600 @default.
• W3086743547 cites W2917666487 @default.
• W3086743547 cites W2948576133 @default.
• W3086743547 cites W2964769047 @default.
• W3086743547 cites W2976970046 @default.
• W3086743547 cites W2980731370 @default.
• W3086743547 cites W2996779061 @default.
• W3086743547 cites W2997295012 @default.
• W3086743547 cites W3002179283 @default.
• W3086743547 doi "https://doi.org/10.1097/cm9.0000000000001004" @default.
• W3086743547 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7546841" @default.
• W3086743547 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32925278" @default.
• W3086743547 hasPublicationYear "2020" @default.
• W3086743547 type Work @default.
• W3086743547 sameAs 3086743547 @default.
• W3086743547 citedByCount "1" @default.
• W3086743547 countsByYear W30867435472021 @default.
• W3086743547 crossrefType "journal-article" @default.
• W3086743547 hasAuthorship W3086743547A5029367861 @default.
• W3086743547 hasAuthorship W3086743547A5044741816 @default.
• W3086743547 hasAuthorship W3086743547A5079347787 @default.
• W3086743547 hasAuthorship W3086743547A5086812005 @default.
• W3086743547 hasBestOaLocation W30867435471 @default.
• W3086743547 hasConcept C126322002 @default.
• W3086743547 hasConcept C164705383 @default.
• W3086743547 hasConcept C2776297358 @default.
• W3086743547 hasConcept C2776988256 @default.
• W3086743547 hasConcept C2777214474 @default.
• W3086743547 hasConcept C2778808290 @default.
• W3086743547 hasConcept C2779065481 @default.
• W3086743547 hasConcept C2779393834 @default.
• W3086743547 hasConcept C2780496750 @default.
• W3086743547 hasConcept C2781025020 @default.
• W3086743547 hasConcept C56900294 @default.
• W3086743547 hasConcept C58245268 @default.
• W3086743547 hasConcept C71924100 @default.
• W3086743547 hasConcept C84393581 @default.
• W3086743547 hasConceptScore W3086743547C126322002 @default.
• W3086743547 hasConceptScore W3086743547C164705383 @default.
• W3086743547 hasConceptScore W3086743547C2776297358 @default.
• W3086743547 hasConceptScore W3086743547C2776988256 @default.
• W3086743547 hasConceptScore W3086743547C2777214474 @default.
• W3086743547 hasConceptScore W3086743547C2778808290 @default.
• W3086743547 hasConceptScore W3086743547C2779065481 @default.
• W3086743547 hasConceptScore W3086743547C2779393834 @default.
• W3086743547 hasConceptScore W3086743547C2780496750 @default.
• W3086743547 hasConceptScore W3086743547C2781025020 @default.
• W3086743547 hasConceptScore W3086743547C56900294 @default.
• W3086743547 hasConceptScore W3086743547C58245268 @default.
• W3086743547 hasConceptScore W3086743547C71924100 @default.
• W3086743547 hasConceptScore W3086743547C84393581 @default.
• W3086743547 hasIssue "19" @default.
• W3086743547 hasLocation W30867435471 @default.
• W3086743547 hasLocation W30867435472 @default.
• W3086743547 hasLocation W30867435473 @default.
• W3086743547 hasOpenAccess W3086743547 @default.
• W3086743547 hasPrimaryLocation W30867435471 @default.
• W3086743547 hasRelatedWork W1499967405 @default.
• W3086743547 hasRelatedWork W154779024 @default.
• W3086743547 hasRelatedWork W157618018 @default.
• W3086743547 hasRelatedWork W2016855390 @default.
• W3086743547 hasRelatedWork W2045471268 @default.
• W3086743547 hasRelatedWork W2087544553 @default.
• W3086743547 hasRelatedWork W2399521485 @default.
• W3086743547 hasRelatedWork W2735845037 @default.
• W3086743547 hasRelatedWork W3086743547 @default.
• W3086743547 hasRelatedWork W4244710917 @default.
• W3086743547 hasVolume "133" @default.
• W3086743547 isParatext "false" @default.
• W3086743547 isRetracted "false" @default.
• W3086743547 magId "3086743547" @default.
• W3086743547 workType "article" @default.